91 related articles for article (PubMed ID: 22734589)
1. Role of antibody-mediated tumor targeting and route of administration in nanoparticle tumor accumulation in vivo.
Chattopadhyay N; Fonge H; Cai Z; Scollard D; Lechtman E; Done SJ; Pignol JP; Reilly RM
Mol Pharm; 2012 Aug; 9(8):2168-79. PubMed ID: 22734589
[TBL] [Abstract][Full Text] [Related]
2. Design and characterization of HER-2-targeted gold nanoparticles for enhanced X-radiation treatment of locally advanced breast cancer.
Chattopadhyay N; Cai Z; Pignol JP; Keller B; Lechtman E; Bendayan R; Reilly RM
Mol Pharm; 2010 Dec; 7(6):2194-206. PubMed ID: 20973534
[TBL] [Abstract][Full Text] [Related]
3. Molecularly targeted gold nanoparticles enhance the radiation response of breast cancer cells and tumor xenografts to X-radiation.
Chattopadhyay N; Cai Z; Kwon YL; Lechtman E; Pignol JP; Reilly RM
Breast Cancer Res Treat; 2013 Jan; 137(1):81-91. PubMed ID: 23160926
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of EGFR-targeted radioimmuno-gold-nanoparticles as a theranostic agent in a tumor animal model.
Kao HW; Lin YY; Chen CC; Chi KH; Tien DC; Hsia CC; Lin MH; Wang HE
Bioorg Med Chem Lett; 2013 Jun; 23(11):3180-5. PubMed ID: 23628334
[TBL] [Abstract][Full Text] [Related]
5. Active targeting of block copolymer micelles with trastuzumab Fab fragments and nuclear localization signal leads to increased tumor uptake and nuclear localization in HER2-overexpressing xenografts.
Hoang B; Ekdawi SN; Reilly RM; Allen C
Mol Pharm; 2013 Nov; 10(11):4229-41. PubMed ID: 24066900
[TBL] [Abstract][Full Text] [Related]
6. Biological characterization of cetuximab-conjugated gold nanoparticles in a tumor animal model.
Kao HW; Lin YY; Chen CC; Chi KH; Tien DC; Hsia CC; Lin WJ; Chen FD; Lin MH; Wang HE
Nanotechnology; 2014 Jul; 25(29):295102. PubMed ID: 24990295
[TBL] [Abstract][Full Text] [Related]
7. Mixed-charge nanoparticles for long circulation, low reticuloendothelial system clearance, and high tumor accumulation.
Liu X; Li H; Chen Y; Jin Q; Ren K; Ji J
Adv Healthc Mater; 2014 Sep; 3(9):1439-47. PubMed ID: 24550205
[TBL] [Abstract][Full Text] [Related]
8. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
Kirpotin DB; Drummond DC; Shao Y; Shalaby MR; Hong K; Nielsen UB; Marks JD; Benz CC; Park JW
Cancer Res; 2006 Jul; 66(13):6732-40. PubMed ID: 16818648
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
10. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
[TBL] [Abstract][Full Text] [Related]
11. Targeting trastuzumab-resistant breast cancer cells with a lentivirus engineered to bind antibodies that recognize HER-2.
Zhang KX; Kim C; Chow E; Chen IS; Jia W; Rennie PS
Breast Cancer Res Treat; 2011 Jan; 125(1):89-97. PubMed ID: 20232140
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the potential of 188Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment.
Luo TY; Tang IC; Wu YL; Hsu KL; Liu SW; Kung HC; Lai PS; Lin WJ
Nucl Med Biol; 2009 Jan; 36(1):81-8. PubMed ID: 19181272
[TBL] [Abstract][Full Text] [Related]
13. Confocal Raman microspectroscopic study of folate receptor-targeted delivery of 6-mercaptopurine-embedded gold nanoparticles in a single cell.
Park J; Jeon WI; Lee SY; Ock KS; Seo JH; Park J; Ganbold EO; Cho K; Song NW; Joo SW
J Biomed Mater Res A; 2012 May; 100(5):1221-8. PubMed ID: 22359274
[TBL] [Abstract][Full Text] [Related]
14. Dendrimer antibody conjugate to target and image HER-2 overexpressing cancer cells.
Otis JB; Zong H; Kotylar A; Yin A; Bhattacharjee S; Wang H; Baker JR; Wang SH
Oncotarget; 2016 Jun; 7(24):36002-36013. PubMed ID: 27144519
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
[TBL] [Abstract][Full Text] [Related]
16. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
17. (89)Zr-labeled anti-endoglin antibody-targeted gold nanoparticles for imaging cancer: implications for future cancer therapy.
Karmani L; Bouchat V; Bouzin C; Levêque P; Labar D; Bol A; Deumer G; Marega R; Bonifazi D; Haufroid V; Michiels C; Grégoire V; Feron O; Lucas S; Vander Borght T; Gallez B
Nanomedicine (Lond); 2014 Sep; 9(13):1923-37. PubMed ID: 24547782
[TBL] [Abstract][Full Text] [Related]
18. A nanoparticle for tumor targeted delivery of oligomers.
Liu X; Wang Y; Hnatowich DJ
Methods Mol Biol; 2011; 764():91-105. PubMed ID: 21748635
[TBL] [Abstract][Full Text] [Related]
19. Gold nanoparticle probes: design and in vitro applications in cancer cell culture.
Unak G; Ozkaya F; Medine EI; Kozgus O; Sakarya S; Bekis R; Unak P; Timur S
Colloids Surf B Biointerfaces; 2012 Feb; 90():217-26. PubMed ID: 22070896
[TBL] [Abstract][Full Text] [Related]
20. Enhanced retention and cellular uptake of nanoparticles in tumors by controlling their aggregation behavior.
Liu X; Chen Y; Li H; Huang N; Jin Q; Ren K; Ji J
ACS Nano; 2013 Jul; 7(7):6244-57. PubMed ID: 23799860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
